TITLE

European patents for DXL technology

PUB. DATE
October 2008
SOURCE
Medical Device Daily;10/31/2008, Vol. 12 Issue 213, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that patent grants were given to InNexus Biotechnology for its next generation of monoclonal antibodies using its Dynamic Cross Linking (DXL) technology. The patents titled "Method of Affinity Cross-Linking Biologically Active, Immunogenic Peptides to Antibodies" were granted in Spain, Germany, France, Great Britain and Italy. The patent entails the use of DXL technology to develop antibodies.
ACCESSION #
35014965

 

Related Articles

  • INNEXUS BIOTECHNOLOGY GETS PATENT GRANTS IN EUROPE.  // Worldwide Biotech;Dec2008, Vol. 20 Issue 12, p8 

    The article reports on the patent grants received by InNexus Biotechnology Inc. in several countries in Europe which further expanded the patent protections of its DXL technology in Europe. The patents are titled Method of Affinity Cross-Linking Biologically Active, Immunogenic Peptides to...

  • Cross-linking Antibodies. Proffitt, Allison // Bio-IT World;Sep2007, Vol. 6 Issue 7, p12 

    The article focuses on the monoclonal antibody DXL625 (CD20) being developed by InNexus Biotechnology for the treatment of non-Hodgkin's lymphoma. InNexus has received $2 million for DXL625 and its total purchase price may be increased to $30 million if certain conditions are fulfilled. The...

  • InNexus and Corixa to develop monoclonal antibodies.  // PharmaWatch: Cancer;October 2003, Vol. 2 Issue 10, p17 

    Reports on an antibody research, development and license agreement between InNexus Biotechnology and Corixa Corp. Terms of the agreement; Development of the anti-tumor activity of selected antibody leads.

  • INNEXUS UNVEILS DXL625 ANTI-CD20 MONOCLONAL ANTIBODY.  // Worldwide Biotech;Oct2007, Vol. 19 Issue 10, p3 

    The article reports on the announcement by InNexus Biotechnology Inc. that significant enhancement of critical performance factors for many monoclonal antibodies appears possible through their Dynamic Cross Linking technology. Findings showed that DXL625, the company's first product candidate,...

  • Financings Roundup.  // BioWorld Today;6/25/2008, Vol. 19 Issue 123, p3 

    The reports on the completion of an offering by InNexus Biotechnology Inc. of Vancouver, British Columbia in June 2008. The brokered private placement is for gross proceeds of C$4.93 million, with a purchase price at 25 cents per unit. The company will also pay a cash fee equivalent to C$330,050...

  • InNexus adds new product to its cancer drug pipeline.  // PharmaWatch: Cancer;Sep2008, Vol. 7 Issue 9, p7 

    The article evaluates the DXLr120 antibody from InNexus Biotechnology Inc.

  • InNexus Bio Expands Team to Focus on Licensing and Partnering.  // Biomedical Market Newsletter;4/14/2011, p70 

    The article announces that Jonathan Drutz was appointed business development director of InNexus Biotechnology Inc., a drug development company in Chandler, Arizona.

  • InNexus Biotechnology Files Patent for Novel AMD Therapeutic.  // Biomedical Market Newsletter;6/19/2011, p546 

    The article reports that biopharmaceutical company Innexus Biotechnology Inc. has filed for patent protection regarding its Age-related Macular Degeneration (AMD) and eye disorder antibody product. It mentions that the product of the company was develop as topical therapy or eye drop for several...

  • InNexus Bio Expands Team to Focus on Licensing and Partnering.  // Biomedical Market Newsletter;4/14/2011, p79 

    The article announces that Jonathan Drutz was appointed business development director at InNexus Biotechnology Inc. in Chandler, Arizona.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics